NEW YORK, Feb. 10 - Ciphergen Biosystems and Biosite have begun a collaboration to discover antibody and protein target components for use in diagnostic assays for cardiovascular disease, the companies said today.
Biosite will provide clinical samples that Ciphergen scientists will analyze using its ProteinChip technology. The companies will search for differentially expressed protein biomarkers that may be useful as diagnostics or with therapeutic potential.
Biosite plans to develop antibodies against key biomarkers discovered in this collaboration. Both firms are entitled to royalties from any products successfully developed and commercialized as a result of the research.
The project will initially focus on cardiovascular disease, an area in which Biosite has already commercialized several diagnostic systems.